Bleomycin disposition in children with cancer

Gary C Yee, William R. Crom, Francis H. Lee, Robert D. Smyth, William E. Evans

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Bleomycin kinetics were determined in 14 children after intravenous bolus and prolonged infusion doses. Plasma and urine bleomycin concentrations were determined by radioimmunoassay. After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t 1 2α and t 1 2β of 0.3 ± 0.1 and 3.2 ± 0.7 hr (mean ± SEM). Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 ± 0.5 and 9.9 ± 1.1 l/m2. Total plasma (CLT) and renal (CLR) clearance were 51.8 ± 6.1 and 33.5 ± 2.4 ml/min/m2. Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (>300 mg/m2); CLT and CLR for these courses were 18.0 ± 3.3 and 8.2 ml/min/m2. Conversely, children under 3 yr old eliminated bleomycin more rapidly than older children. Decline in bleomycin concentrations after seven 24-or 48-hr intravenous infusions was described by a one-compartment model. Mean values for plasma t 1 2, Vss, CLT, and CLR were 2.1 ± 0.1 hr, 11.0 ± 2.6 1/m2, 57.1 ± 13.5 ml/min/m2, and 33.2 ± 6.4 ml/min/m2. One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2. These data indicate that young children eliminate bleomycin more rapidly than older children and that children with impaired renal function may have prolonged elevations in plasma concentration due to reduced bleomycin clearance. Bleomycin disposition in older children is as in adults.

Original languageEnglish (US)
Pages (from-to)668-673
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume33
Issue number5
DOIs
StatePublished - Jan 1 1983

Fingerprint

Bleomycin
Kidney
Neoplasms
Ureteral Obstruction
indium-bleomycin
Intravenous Infusions
Cisplatin
Radioimmunoassay
Urine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bleomycin disposition in children with cancer. / Yee, Gary C; Crom, William R.; Lee, Francis H.; Smyth, Robert D.; Evans, William E.

In: Clinical Pharmacology and Therapeutics, Vol. 33, No. 5, 01.01.1983, p. 668-673.

Research output: Contribution to journalArticle

Yee, GC, Crom, WR, Lee, FH, Smyth, RD & Evans, WE 1983, 'Bleomycin disposition in children with cancer', Clinical Pharmacology and Therapeutics, vol. 33, no. 5, pp. 668-673. https://doi.org/10.1038/clpt.1983.91
Yee, Gary C ; Crom, William R. ; Lee, Francis H. ; Smyth, Robert D. ; Evans, William E. / Bleomycin disposition in children with cancer. In: Clinical Pharmacology and Therapeutics. 1983 ; Vol. 33, No. 5. pp. 668-673.
@article{e41d1ab85ac948cfb2aa05c0c4a32bd0,
title = "Bleomycin disposition in children with cancer",
abstract = "Bleomycin kinetics were determined in 14 children after intravenous bolus and prolonged infusion doses. Plasma and urine bleomycin concentrations were determined by radioimmunoassay. After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t 1 2α and t 1 2β of 0.3 ± 0.1 and 3.2 ± 0.7 hr (mean ± SEM). Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 ± 0.5 and 9.9 ± 1.1 l/m2. Total plasma (CLT) and renal (CLR) clearance were 51.8 ± 6.1 and 33.5 ± 2.4 ml/min/m2. Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (>300 mg/m2); CLT and CLR for these courses were 18.0 ± 3.3 and 8.2 ml/min/m2. Conversely, children under 3 yr old eliminated bleomycin more rapidly than older children. Decline in bleomycin concentrations after seven 24-or 48-hr intravenous infusions was described by a one-compartment model. Mean values for plasma t 1 2, Vss, CLT, and CLR were 2.1 ± 0.1 hr, 11.0 ± 2.6 1/m2, 57.1 ± 13.5 ml/min/m2, and 33.2 ± 6.4 ml/min/m2. One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2. These data indicate that young children eliminate bleomycin more rapidly than older children and that children with impaired renal function may have prolonged elevations in plasma concentration due to reduced bleomycin clearance. Bleomycin disposition in older children is as in adults.",
author = "Yee, {Gary C} and Crom, {William R.} and Lee, {Francis H.} and Smyth, {Robert D.} and Evans, {William E.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1038/clpt.1983.91",
language = "English (US)",
volume = "33",
pages = "668--673",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Bleomycin disposition in children with cancer

AU - Yee, Gary C

AU - Crom, William R.

AU - Lee, Francis H.

AU - Smyth, Robert D.

AU - Evans, William E.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Bleomycin kinetics were determined in 14 children after intravenous bolus and prolonged infusion doses. Plasma and urine bleomycin concentrations were determined by radioimmunoassay. After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t 1 2α and t 1 2β of 0.3 ± 0.1 and 3.2 ± 0.7 hr (mean ± SEM). Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 ± 0.5 and 9.9 ± 1.1 l/m2. Total plasma (CLT) and renal (CLR) clearance were 51.8 ± 6.1 and 33.5 ± 2.4 ml/min/m2. Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (>300 mg/m2); CLT and CLR for these courses were 18.0 ± 3.3 and 8.2 ml/min/m2. Conversely, children under 3 yr old eliminated bleomycin more rapidly than older children. Decline in bleomycin concentrations after seven 24-or 48-hr intravenous infusions was described by a one-compartment model. Mean values for plasma t 1 2, Vss, CLT, and CLR were 2.1 ± 0.1 hr, 11.0 ± 2.6 1/m2, 57.1 ± 13.5 ml/min/m2, and 33.2 ± 6.4 ml/min/m2. One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2. These data indicate that young children eliminate bleomycin more rapidly than older children and that children with impaired renal function may have prolonged elevations in plasma concentration due to reduced bleomycin clearance. Bleomycin disposition in older children is as in adults.

AB - Bleomycin kinetics were determined in 14 children after intravenous bolus and prolonged infusion doses. Plasma and urine bleomycin concentrations were determined by radioimmunoassay. After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t 1 2α and t 1 2β of 0.3 ± 0.1 and 3.2 ± 0.7 hr (mean ± SEM). Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 ± 0.5 and 9.9 ± 1.1 l/m2. Total plasma (CLT) and renal (CLR) clearance were 51.8 ± 6.1 and 33.5 ± 2.4 ml/min/m2. Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (>300 mg/m2); CLT and CLR for these courses were 18.0 ± 3.3 and 8.2 ml/min/m2. Conversely, children under 3 yr old eliminated bleomycin more rapidly than older children. Decline in bleomycin concentrations after seven 24-or 48-hr intravenous infusions was described by a one-compartment model. Mean values for plasma t 1 2, Vss, CLT, and CLR were 2.1 ± 0.1 hr, 11.0 ± 2.6 1/m2, 57.1 ± 13.5 ml/min/m2, and 33.2 ± 6.4 ml/min/m2. One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2. These data indicate that young children eliminate bleomycin more rapidly than older children and that children with impaired renal function may have prolonged elevations in plasma concentration due to reduced bleomycin clearance. Bleomycin disposition in older children is as in adults.

UR - http://www.scopus.com/inward/record.url?scp=0020504936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020504936&partnerID=8YFLogxK

U2 - 10.1038/clpt.1983.91

DO - 10.1038/clpt.1983.91

M3 - Article

VL - 33

SP - 668

EP - 673

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -